Skip to content
3 min read Therapeutic Thursday therapeutic-thursday

Therapeutic Thursday: Waiting On The World (Of HS) To Change

Three approved biologics and a packed pipeline later, hidradenitis suppurativa’s biggest problem is still getting patients treated.

a wall with four neon signs spelling out the word "waiting" with each sign lit to a different brightness
HS conferences have gone from an empty room to standing room only. Now the real change begins. Photo by Levi Meir Clancy on Unsplash.

Plot twist: Aakash and I swapped days this week. He took my Tuesday slot (did you notice?), so you’re stuck with me for Therapeutic Thursday. Let’s dig in.

From being one of dermatology’s most neglected stories to becoming a potential multibillion-dollar treatment market being targeted by several large pharmas, hidradenitis suppurativa (HS) has experienced a sea change.

Dr. Steven Daveluy, whom I spoke with for a market snapshot I wrote about the disease in June, described the HS conferences of yore as quiet, close-knit affairs. “At our dermatology conferences, the room, when we talked about HS, used to be very small – you knew everyone in the room. But now that there’s [an] approved therapy, so many derms are re-engaging that the rooms are overfilled, standing room only,” said Daveluy, who is a professor of dermatology at Wayne State University in Detroit.

Loving Capsul? Help us share the word. We put a lot into every edition. Refer Capsul News to someone who'd find it valuable, get a shoutout in our newsletter, and the top two referrers each win a gift card. Refer a friend

The treatment landscape has changed dramatically over the past few years. But conversations with dermatologists, analysts and pharma executives revealed some holes in the existing treatment paradigms and, with them, opportunities for new entrants.